Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Acute Disseminated Demyelination Treatment Market size was over USD 10.99 billion in 2024 and is anticipated to cross USD 20.47 billion by 2037, witnessing more than 4.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of acute disseminated demyelination treatment is estimated at USD 11.87 billion.
The growth of this market can be attributed to the growing prevalence of acute disseminated demyelination disease worldwide with the rise in some recorded cases in recent times. As per our estimations, acute disseminated demyelination is expected to occur in approximately 0.8-2.0 cases per 100,000 individuals per year. Acute disseminated demyelination is more common in children and occurs more frequently in males than females.
Moreover, the rising prevalence of autoimmune diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has increased the demand for acute disseminated demyelination treatment. The National Multiple Sclerosis Society reports that the prevalence of MS is increasing worldwide, affecting an estimated 2.8 million people worldwide. NMOSD is becoming more common, especially in Asia, with a prevalence of 0.05–10 per 100,000 people.
Acute Disseminated Demyelination Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Autoimmune Diseases Across the Globe – The rising presence of autoimmune diseases all over the world is estimated to drive the growth of this market in the forecast period. The number of people with autoimmune diseases is steadily increasing in the UK. The NHS estimates that around 4 million people in the UK suffer from autoimmune diseases and that number is rising.
- Rising Number of Cases of Acute Disseminated Demyelination – Growing number of cases of acute disseminated demyelination is expected to drive the market in the forecast period owing to greater demand for the treatment. A study conducted in the United States and published in the journal Neurology in 2020 reported high occurrence of acute disseminated demyelination in children. The study found that from 2007 to 2016, the annual incidence of the disease in children aged 0 to 17 years was 0.53 cases per 100,000 person-years.
- Development of Advanced Therapeutics - The development of advanced therapeutics such as monoclonal antibodies and immunomodulatory agents is driving the growth of the acute disseminated demyelination treatment market. For instance, in 2020 Alexion Pharmaceuticals received FDA approval for Ultomiris, a monoclonal antibody for the treatment of NMOSD that is also used off-label to treat ADEM. Similarly, Novartis received FDA approval in 2019 for Mayzent, an oral drug used to treat MS that also has the potential to treat ADEM.
- Growing Awareness about Neurological Disorder – Acute disseminated demyelination is a neurological disorder that widely takes place in children and females. Thus, growing awareness about neurological disorders is expected to drive market growth. In the European Union, the European Brain Council (EBC) is a non-profit organization dedicated to promoting research, education, and awareness of brain diseases. The EBC estimates that about 220 million people in Europe suffer from neurological disorders, and this number is expected to increase as the population ages.
Challenges
- High Cost of Treatment - ADEM treatment can be expensive, especially for patients requiring hospitalization or long-term care. This can place a huge financial burden on patients, their families, and the healthcare system.
- Poor Health Infrastructure in Underdeveloped Nations
- Lack of Awareness About the Treatment
Acute Disseminated Demyelination Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.9% |
|
Base Year Market Size (2024) |
USD 10.99 billion |
|
Forecast Year Market Size (2037) |
USD 20.47 billion |
|
Regional Scope |
|
Global Acute Disseminated Demyelination Treatment Market Segmentation
Treatment Type (Corticosteroids, Immunoglobulin (IVIg) Therapy, Plasmapheresis)
The global acute disseminated demyelination treatment market is segmented and analyzed for demand and supply by treatment type into corticosteroids, immunoglobulin (IVIg) therapy, plasmapheresis, and others. Out of these, the corticosteroids segment is anticipated to hold the largest market share by the end of 2037. This can be attributed on the account of widespread acceptance of intravenous corticosteroids as first-line treatment for this condition. Studies have shown that high-dose corticosteroids can reduce inflammation and improve clinical outcomes in patients with ADEM.
End User (Hospitals, Clinics, Ambulatory Surgical Centers)
The global market is segmented and analyzed for demand and supply by end-user into hospitals, clinics, ambulatory surgical centers, and others. Out of these, the hospital segment is anticipated to hold the largest market share by the end of 2037. Hospitals offer a variety of treatment options for acute disseminated demyelination patients, including high-dose corticosteroids, intravenous immunoglobulins, and plasmapheresis. In severe cases, patients may require hospitalization for monitoring and supportive care. The hospital also offers diagnostic services for acute disseminated demyelination patients, such as MRI scans, spinal taps, and blood tests. These tests are essential in diagnosing acute disseminated demyelination and monitoring disease progression. The hospital employs a variety of medical professionals trained in diagnosing and treating neurological disorders, including neurologists, neurosurgeons, and neurointensive care specialists. These professionals play an important role in the care of acute disseminated demyelination ADEM patients.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment Type |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAcute Disseminated Demyelination Treatment Industry - Regional Synopsis
North American Market Forecast
North America industry is set to hold largest revenue share by 2037, owing to develop an effective treatment for acute disseminated demyelination in the region.As per the National Health Expenditure Account (NHEA), total healthcare spending in the United States grew 4.6 percent in 2019, reaching USD 3.8 trillion or USD 11,582 per person. As a share of the nation's gross domestic product (GDP), health spending accounted for 17.7 percent. North America has a well-established medical infrastructure that includes advanced diagnostic and therapeutic technologies. This infrastructure is designed to support the growth of the market. The United States in particular is one of the world's most expensive countries for healthcare. This high level of spending is estimated to support the growth of the market in North America.
APAC Market Statistics
The market in the Asia Pacific is estimated to witness noteworthy over the forecast period on the back of the large patient pool, rising developments in healthcare facilities in emerging economies namely China and India, and growing government investments to improve healthcare infrastructure in the region. The rising presence of this health disorder in the region and growing awareness about this health problem among healthcare professionals in the Asia-Pacific region is expected to drive the growth of the market in the Asia-Pacific region. This area is home to several significant corporations that are further making investments in R&D to create fresh, efficient therapies for acute disseminated demyelination. In addition to pharmaceutical firms, the Asia Pacific region is home to numerous research organizations, hospitals, clinical trials, and research studies on acute disseminated demyelination treatment. This is anticipated to spur commercial innovation and result in the creation of novel treatment choices for acute disseminated demyelination patients. Governments and private organizations in the Asia-Pacific region are increasing their investment in healthcare infrastructure and technology, which is expected to boost the growth of the acute disseminated demyelination treatment market.
Europe Market Forecast
The market in the Europe region is anticipated to hold a significant market share in the forecast period. ADEM is a rare autoimmune disease that affects the central nervous system and can have serious long-term consequences if left untreated. European governments and private organizations are increasing their investment in medical infrastructure and technology, which is expected to drive the growth of the market. The market for acute disseminated demyelination treatment in Europe is influenced by a number of variables, including the rising incidence of neurological illnesses, the rising desire for efficient therapies, and developments in medical technology. Government programs to upgrade the healthcare system, rising healthcare costs, and rising public knowledge of the condition are further variables that have an impact on the market.
Companies Dominating the Acute Disseminated Demyelination Treatment Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson & Johnson Service, Inc.
- Novartis AG
- Merck & Co. GmbH
- F. Hoffman-La Roche AG
- Sanofi SA
- Bayer AG
- GlaxoSmithKline plc
- Abbott Laboratories
- Amgen, Inc.
In the News
- The European Union has authorized Biogen Inc.'s medication Tysabri (natalizumab) for the treatment of acute diffuse demyelination. A monoclonal antibody called Tysabri, which targets immune cells, is intended to lessen the inflammation brought on by acute disseminated demyelination.
- The European Union has approved Novartis International AG's medication Kesimpta (ofatumumab) for the treatment of acute disseminated demyelination. Kesimpta is a monoclonal antibody that is injected under the skin and targets immune cells.
Author Credits: Radhika Pawar
- Report ID: 4933
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
